2-(4-hydroxyphenyl)propionic acid | 124578-19-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-(4-hydroxyphenyl)propionic acid
• 英文别名: 2-HPPA；(S)-2-(4-hydroxy-phenyl)-propionic acid；(S)-2-(4-Hydroxy-phenyl)-propionsaeure；(S)-(+)-2-(4-hydroxyphenyl)propionic acid；2-(4-Hydroxyphenyl)propionic acid, (2S)-；(2S)-2-(4-hydroxyphenyl)propanoic acid
• CAS: 124578-19-4
• 化学式: C₉H₁₀O₃
• 分子量: 166.177
• InChiKey: ZHMMPVANGNPCBW-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-hydroxyphenyl)propionic acid 、 溴丙酮 在 三乙胺 作用下， 以 氯仿 为溶剂， 生成 (S)-(+)-2-(4-hydroxyphenyl)propionic acid methylcarbonylmethyl ester
  参考文献：
  名称：

  EP673924

  摘要：

  公开号：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 作用下， 生成 2-(4-hydroxyphenyl)propionic acid
  参考文献：
  名称：

  A separation method for DNA computing based on concentration control

  摘要：

  A separation method for DNA computing based on concentration control is presented. The concentration control method was earlier developed and has enabled us to use DNA concentrations as input data and as filters to extract target DNA. We have also applied the method to the shortest path problems, and have shown the potential of concentration control to solve large-scale combinatorial optimization problems. However, it is still quite difficult to separate different DNA with the same length and to quantify individual DNA concentrations. To overcome these difficulties, we use DGGE and CDGE in this paper. We demonstrate that the proposed method enables us to separate different DNA with the same length efficiently, and we actually solve an instance of the shortest path problems.

  DOI：

  10.1007/bf03037359

文献信息

• Lipase-catalyzed hydrolysis of 2-(4-hydroxyphenyl)propionic acid ethyl ester to (R)-(−)-2-(4-hydroxyphenyl)propanoic acid
  作者：Xin Yuan、Panliang Zhang、Guangyong Liu、Weifeng Xu、Kewen Tang

  DOI：10.1007/s11696-019-00796-9

  日期：2019.10

  Stereoselective hydrolysis of (±)-2-(4-hydroxyphenyl)propionic acid ethyl ester (2-HPPAEE) by lipase catalyzed in aqueous system was investigated. Lipase AK with higher catalytic activity and enantioselectivity was selected as catalyst. Simultaneously, factors affecting the conversion of substrate (c) and the enantiomeric excess of product (eep) were optimized. The optimal conditions were established

  研究了水体系中脂肪酶催化的（±）-2-（4-羟苯基）丙酸乙酯（2-HPPAEE）的立体选择性水解。选择具有较高催化活性和对映选择性的脂肪酶AK作为催化剂。同时，优化了影响底物（c）转化和产物的对映体过量（ee p）的因素。确定了最佳条件，包括温度45°C，pH 5.5，脂肪酶AK剂量10 mg，底物剂量0.04 mmol和反应时间40 h。在最佳条件下，c和ee p分别可达49％和98％。
• [EN] 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] ACIDES 2-ARYL-PROPIONIQUES ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI
  申请人：DOMPE SPA

  公开号：WO2003043625A1

  公开（公告）日：2003-05-30

  (R) and (S) 2-Aryl-propionic acids, and pharmaceutical compositions that contain them, are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The acids are used for the prevention and treatment of pathologies deriving from said activation. In particular, the (R) enantiomers of said acids are lacking cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD),bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

  (R)和(S) 2-芳基丙酸及含有它们的药物组合物，可用于抑制由白细胞介素-8（IL-8）与CXCR1和CXCR2膜受体相互作用引起的嗜中性粒细胞（PMN白细胞）的趋化活化。这些酸用于预防和治疗由该活化引起的病理。特别地，这些酸的(R)对映体缺乏环氧合酶抑制活性，特别适用于治疗依赖于中性粒细胞的病理，如银屑病，溃疡性结肠炎，黑色素瘤，慢性阻塞性肺疾病（COPD），天疱疮，类风湿性关节炎，特发性纤维化，肾小球肾炎以及缺血再灌注所致的损伤的预防和治疗。
• 2-Aryl-propionic acids and pharmaceutical compositions containing them
  申请人：Allegretti Marcello

  公开号：US20050038119A1

  公开（公告）日：2005-02-17

  (R) and (S) 2-Aryl-propionic acids, and pharmaceutical compositions that contain them, are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The acids are used for the prevention and treatment of pathologies deriving from said activation. In particular, the (R) enantiomers of said acids are lacking cyclo-oxygenase inhibition activity and are particularly useful in the tratment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

  (R)和(S) 2-芳基-丙酸以及含有它们的制药组合物，在抑制由白细胞介素-8（IL-8）与CXCR1和CXCR2膜受体相互作用引起的嗜中性粒细胞（PMN白细胞）趋化激活方面非常有用。这些酸用于预防和治疗由该激活引起的病理状况。特别是，这些酸的(R)对映体缺乏环氧合酶抑制活性，特别适用于治疗依赖于嗜中性粒细胞的病理状况，如牛皮癣，溃疡性结肠炎，黑色素瘤，慢性阻塞性肺疾病（COPD），水疱性天疱疮，类风湿性关节炎，特发性纤维化，肾小球肾炎以及缺血再灌注所致的损伤的预防和治疗。
• HETEROARYL INHIBITORS OF PDE4
  申请人：Tetra Discovery Partners, LLC

  公开号：US20150119362A1

  公开（公告）日：2015-04-30

  The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.

  本发明涉及化合物和方法，用于作为磷酸二酯酶4（PDE4）的抑制剂，用于治疗或预防疾病。
• BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS
  申请人：Gallant Michel

  公开号：US20130244929A1

  公开（公告）日：2013-09-19

  The present invention provides novel lipoglycopeptide compounds which are Type 1 signal peptidase inhibitors (SpsB). Compounds of the present invention are useful for the treatment of various bacterial related infectious diseases, particularly when used as a potentiator of a β-lactam antibiotic such as imipenem and ertapenem. Accordingly, the present invention provides a method for the treatment of bacterial related infections using the compounds described herein, either alone or in combination with a β-lactam antibiotic.

  本发明提供了一种新型的脂肽多糖肽类化合物，它们是一类信号肽酶抑制剂（SpsB）。本发明的化合物可用于治疗各种细菌相关感染疾病，特别是在与β-内酰胺类抗生素（如亚胺培南和依达拉奉）一起使用时作为增效剂。因此，本发明提供了一种使用本文所述化合物单独或与β-内酰胺类抗生素联合治疗细菌相关感染的方法。